NeuroDiscovery AI plans to raise USD 100m to USD 150m in the first half of 2027 and will hire an advisor for that process, according to founder and CEO Vamsi Chandra Kasivajjala.

The artificial intelligence platform (AI) for neurology data, diagnostics, and clinical trial recruitment is currently raising a USD 10m round, which it expects to complete in June or July, Kasivajjala said. Proceeds will fund a USD 2m AI model upgrade, salesforce expansion, the onboarding of 150 to 200 new provider data partnerships, and increased cold-storage capacity for biological samples used in DNA and RNA sequencing.

The larger raise next year will fund the formation of a sequencing laboratory, at a projected USD 20m-USD 40m capital cost and USD 5m annual operating cost over three years, and a brain research institute, at an approximately USD 7m-USD 8m operating cost over three years, the CEO said.

Using a proprietary platform and data extracted from close to 6m de-identified US neurology patient records, Alpharetta, Georgia-based NeuroDiscovery helps pharmaceutical firms and healthcare providers accelerate clinical trials, analyze real-world patient data, and generate evidence for neurological diseases including Alzheimer’s, Parkinson’s, epilepsy, migraine and multiple sclerosis.

The platform can compress neurology clinical trial recruitment from the typical 18 months or longer to five to eight weeks, according to Kasivajjala.

NeuroDiscovery achieved profitability in December 2025 and is debt free. The company is projecting approximately USD 14m in annual recurring revenue (ARR) in 2026, USD 40m to USD 50m in 2027, and USD 300m to USD 500m by 2029 or 2030, at which point Kasivajjala said the business should be positioned to exit.

The company could exit via a sale or IPO, with Kasivajjala noting adjacent player Tempus AI, which trades at approximately 9.3x revenue, as the closest public comparable. However, the more likely outcome is a sale to a pharmaceutical company or health insurer, given NeuroDiscovery’s large data set, the CEO said.

By next year, most of NeuroDiscovery’s one-year contracts are expected to convert into three- to five-year agreements, driving growth alongside a land-and-expand strategy in which pharmaceutical customers initially engage within one division before expanding across additional divisions, Kasivajjala said.

NeuroDiscovery has grown organically to date but is now looking to acquire a small US-based electronic health record company and a small laboratory, he added.

Kasivajjala founded NeuroDiscovery in December 2023 and owns the majority stake. The remainder is held by neurologists, neurosurgeons and neurology hospital administrators who have invested approximately USD 6m into the business, he said.

A computer science engineer by training, Kasivajjala previously co-founded document automation company Foundation AI and healthcare analytics platform Enlightiks, which was acquired by Practo in 2016 for approximately USD 14m.

NeuroDiscovery expects to grow its patient dataset to 8m to 10m by year-end through partnerships with more than 1,000 neurology providers, with a target of 20m US neurology patients by the end of 2027 and 30m by 2029, representing approximately 50% market penetration, according to Kasivajjala.

The company has around 10 customers, primarily mid-size to large pharmaceutical and biotech companies, the CEO noted.

NeuroDiscovery competes with clinical trial recruitment and real-world data platforms operating across multiple therapeutic areas, including AutoCruitment, TriNetX, Inato, SubjectWell and Trially. It differentiates itself through its exclusive neurology focus, Kasivajjala said.

Adjacent players include IQVIA, Veradigm, Medidata Solutions, Tempus, ConcertAI, Deep 6 AI, and Flatiron Health, which Kasivajjala said could serve as either competitors or partners.

Recent sector deal activity, according to the CEO, includes QHP Capital’s 2022 acquisition of AutoCruitment; WindRose Health Investors’ 2024 acquisition of SubjectWell, which it later merged with Clariness in 2026 to form a larger global patient recruitment platform under the Clariness name; TriNetX’s 2025 joint venture with Fujitsu to expand clinical trial access in Japan; and TriNetX’s April 2026 acquisition of assets from Zetta Genomics to expand its genomics capabilities.

NeuroDiscovery has approximately 80 employees, around 30% based in the US and the remainder in Bangalore, India. The company uses Wilson Sonsini as legal counsel.